Navigation Links
Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Date:2/5/2009

ibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Cloud ... drug design and development, announced today the expansion ... company has been granted supercomputing time at Argonne ... targets.  Through a discretionary allocation ... Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will ...
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... CAMBRIDGE, Mass. , July 14, 2014 ... in the development of new therapies to treat neuropsychiatric ... Ahlholm has been appointed vice president of finance ... Mr. Ahlholm is a senior executive with more ... functions at technology and life science companies. His background ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... registry platform, announced that three PatientCrossroads-based patient ... the Phelan-McDermid Syndrome International Registry; and the ... been awarded contracts by the Patient-Centered Outcomes ... creation of a new health data network ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Md., Aug. 30 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Germany on Wednesday,September 5, 2007 at 9:50am Eastern ...
... Aug. 29 Sucampo,Pharmaceuticals, Inc. (Nasdaq: SCMP ) ... have exercised in full their option to,purchase 562,500 shares ... that the closing of that purchase took place on ... closing were sold by a selling,stockholder and Sucampo did ...
... Mass., Aug. 29 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... presentation,at the Thomas Weisel Partners 2007 Healthcare ... accessed by visiting the Investors section of ... http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) The presentation ...
Cached Biology Technology:Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2Sucampo Pharmaceuticals Announces Exercise and Closing of IPO Over-Allotment Option 2Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2
(Date:7/14/2014)... the discovery and description of Rhipidocyrtus muiri - ... out to represent a new genus and species. The long ... Borneo is discussed in a recent paper published in the ... holotype male, and only known specimen of Rhipidocyrtus muiri ... to this it was transferred among several researchers in the ...
(Date:7/14/2014)... in the local environment manage much better in the ... environments. , A world without bees would be ... an additional 600 million to 1 billion Danish kroner ... bees making honey and pollinating a wide range of ... bees all over the world are under pressure from ...
(Date:7/14/2014)... Roquin protein, discovered in 2005, controls T-cell activation ... mRNAs. In doing so, it helps to guarantee ... body,s own structures that can lead to autoimmune ... diseases affect between five and ten per cent ... result of complex environmental influences when a genetic ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Best for bees to be stay-at-homes 2Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2
... Boston University have taught bacteria how to count. Professor ... sequence of genes that allow the microbes to count ... potential applications, which could include drug delivery and sensing ... application still to be addressed within synthetic biology: Can ...
... Each year the American Institute of Biological ... outstanding contributions to the biological sciences. Since ... annually to individuals who have made significant scientific ... fields of integrative and organismal biology. The ...
... Ludwig Institute for Cancer Research at the University of ... remarkable property of the contractile ring, a structure required ... works to divide the cell may facilitate development of ... The researchers show that even though both ...
Cached Biology News:Boston University biomedical engineers teach bacteria to count 2Boston University biomedical engineers teach bacteria to count 3Two Central High (Philadelphia) grads honored by AIBS 2Study may aid efforts to prevent uncontrolled cell division in cancer 2
Protein Kinase D2 Immunogen: Human protein kinase D2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... Upright Freezer Inventory Storage Racks for ... available to fit all makes and ... Made of high quality stainless ... high fiberboard, stainless steel or plastic ...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Biology Products: